Nova Eye Medical Limited
Nova Eye Medical Limited (ELXMF) Financial Performance & Income Statement Overview
Review Nova Eye Medical Limited (ELXMF) income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Nova Eye Medical Limited (ELXMF) Income Statement & Financial Overview
View the income breakdown for Nova Eye Medical Limited ELXMF across both annual and quarterly reports.
| Metric | Q4 2024 | Q2 2024 | Q4 2023 | Q2 2023 |
|---|---|---|---|---|
| Revenue | $13.19M | $10.14M | $8.63M | $8.39M |
| Cost of Revenue | $1.93M | $8.82M | $7.21M | $8.98M |
| Gross Profit | $11.26M | $1.32M | $1.43M | -$586000.00 |
| Gross Profit Ratio | $0.85 | $0.13 | $0.17 | -$0.07 |
| R&D Expenses | $567000.00 | $0.00 | $617000.00 | $0.00 |
| SG&A Expenses | $11.48M | $6.93M | $4.09M | $6.65M |
| Operating Expenses | $12.05M | $6.93M | $6.06M | $6.42M |
| Total Costs & Expenses | $13.97M | $15.74M | $13.27M | $15.39M |
| Interest Income | $73000.00 | $51000.00 | $68000.00 | $35000.00 |
| Interest Expense | $58000.00 | $12000.00 | $25000.00 | $29000.00 |
| Depreciation & Amortization | $1.57M | $1.42M | $1.18M | $1.11M |
| EBITDA | -$1.54M | -$4.18M | -$3.36M | -$5.89M |
| EBITDA Ratio | -$0.12 | -$0.41 | -$0.40 | -$0.70 |
| Operating Income | -$786000.00 | -$5.61M | -$4.63M | -$7.004M |
| Operating Income Ratio | -$0.06 | -$0.55 | -$0.54 | -$0.83 |
| Other Income/Expenses (Net) | -$2.38M | -$19000.00 | -$6.91M | -$30000.00 |
| Income Before Tax | -$3.17M | -$5.63M | -$9.97M | -$7.03M |
| Income Before Tax Ratio | -$0.24 | -$0.55 | -$1.15 | -$0.84 |
| Income Tax Expense | $0.00 | $0.00 | -$1.28M | -$429000.00 |
| Net Income | -$3.17M | -$5.63M | -$8.69M | -$6.61M |
| Net Income Ratio | -$0.24 | -$0.55 | -$1.006 | -$0.79 |
| EPS | -$0.01 | -$0.03 | -$0.05 | -$0.04 |
| Diluted EPS | -$0.01 | -$0.03 | -$0.05 | -$0.04 |
| Weighted Avg Shares Outstanding | $217.03M | $195.77M | $169.12M | $149.74M |
| Weighted Avg Shares Outstanding (Diluted) | $217.60M | $195.77M | $169.12M | $149.74M |
Over the last four quarters, Nova Eye Medical Limited achieved steady financial progress, growing revenue from $8.39M in Q2 2023 to $13.19M in Q4 2024. Gross profit stayed firm with margins at 85% in Q4 2024 versus -7% in Q2 2023. Operating income totaled -$786000.00 in Q4 2024, maintaining a -6% margin over recent quarters. Despite shifts in R&D and SG&A costs, EBITDA stayed strong at -$1.54M. Net income rose to -$3.17M, with EPS at -$0.01. Disciplined expense strategies and efficient operations ensured sustained profitability and long-term financial stability.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan